VLP-Based Antibody-Inducing Vaccines for HIV-1

基于 VLP 的 HIV-1 抗体诱导疫苗

• 批准号: 7845275
• 负责人: Robert G. Whalen
• 金额: $ 29.98万
• 依托单位: ALTRAVAX, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-16 至 2012-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7845275
• 关键词: AIDS/HIV problem; Address; Animals; Antibodies; Antibody Formation; Antigens; Autologous; Binding; Capsid; Cellular Membrane; Cessation of life; Clinical; Clinical Trials; Complex; Dissociation; Epidemic; Epitopes; Failure; Genetic; Glycoproteins; HIV; HIV Envelope Protein gp120; HIV-1; HIV-1 vaccine; Hepatitis B Virus; Immunization; In Vitro; Infection; Infection prevention; Length; Life; Ligands; Measures; Membrane; Nature; Oryctolagus cuniculus; Patients; Phase; Physiological; Primates; Process; Production; Property; Public Health; Recombinants; Relative (related person); Research; Research Proposals; Small Business Innovation Research Grant; Structure; Surface; Surface Antigens; T-Lymphocyte; Vaccines; Viral; Viral Envelope Proteins; Virus; Virus-like particle; Vision; Work; base; design; env Gene Products; gag Gene Products; gp160; immunogenic; immunogenicity; improved; neutralizing antibody; neutralizing monoclonal antibodies; nonhuman primate; particle; polypeptide; prevent; public health relevance; vaccine candidate; vaccine development

DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with monomeric recombinant forms of viral envelope (Env) proteins. However, it is clear that the HIV-1 Env contains epitopes that can induce neutralizing antibodies and that such antibodies can protect primates from infection. The HIV-1 Env is a transmembrane glycoprotein. Both the external subunit (gp120) and the membrane- proximal external region of Env (located within the gp41 subunit) contain epitopes that are the target of broadly neutralizing monoclonal antibodies (mAbs) isolated from infected patients. Considerable effort has been devoted to creating soluble forms of the Env trimer. The improvements in immunogenicity of these molecules relative to monomeric gp120 are limited at best. Another approach to creating improved Env-based immunogens is to produce virus-like particles (VLP). VLPs are multivalent and often very immunogenic. The full-length HIV-1 Env protein can be presented on the surface of VLPs composed of Gag protein and cellular membrane components. These VLP structures have the potential to represent true mimics of the Env trimer spike. Several challenges must be overcome to create HIV-1 vaccines based on VLPs. They must be produced at high levels. The number of Env molecules on each VLP must be maximized. Processing of the gp160 Env polypeptide must take place, without dissociation of the gp120 subunit, to create a functional form of the Env trimer. It might also be necessary to minimize the immunogenicity of the variable sequences. In preliminary studies on the creation of VLPs carrying HIV-1 Env proteins, we have begun to address the challenges outlined above. The preliminary results are encouraging and provide a basis for more detailed work on preparing VLP-based immunogens as candidates for HIV-1 vaccines. The objective is to create VLPs that carry the Env protein in a form that most resembles the current vision of the functional Env trimer of the virus. The Specific Aims of this Phase I SBIR proposal are as follows: (1) prepare optimized Env constructs for VLP production; (2) prepare VLP constructs with different Env sequences; and (3) evaluate the ability of various VLPs to induce neutralizing antibodies in rabbits If the VLP-based Env immunogens prove to be superior to soluble gp120 or gp140 constructs in their ability to induce neutralizing antibodies, then additional studies will form the basis of a Phase II SBIR proposal. PUBLIC HEALTH RELEVANCE: The HIV/AIDS epidemic has resulted in 2 million deaths and 2.7 million new infections in 2007, for a total of nearly 33 million people living with HIV/AIDS. Development of a vaccine is considered to be an essential component of the public health measures needed to slow the epidemic. This research proposal is designed to create a vaccine that can induce antibodies capable of preventing infection by the HIV virus.

描述（由申请人提供）：艾滋病毒-1流行病在2007年造成约270万新感染，使艾滋病毒/艾滋病感染者总数达到约3300万。临床试验表明，用病毒包膜（Env）蛋白的单体重组形式免疫不能预防HIV-1感染。然而，很明显，HIV-1 Env含有可以诱导中和抗体的表位，并且这种抗体可以保护灵长类动物免受感染。